Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Preclinical development of SGN-CD47M: Protease-activated antibody technology enables selective tumor targeting of the innate immune checkpoint receptor CD47.

Autor: Levengood MR; Pfizer (United States), Bothell, United States., Carosino CM; Pfizer (United States), Bothell, United States., Zhang X; Pfizer (United States), Bothell, WA, United States., Lucas S; Pfizer (United States), Bothell, United States., Ortiz DJ; Pfizer (United States), Bothell, United States., Westendorf L; Pfizer (United States), Bothell, WA, United States., Chin AP; Pfizer (United States), Bothell, United States., Martin AD; Pfizer (United States), Bothell, United States., Wong A; Pfizer (United States), Bothell, WA, United States., Hengel SM; Pfizer (United States), Bothell, United States., Sun H; Pfizer (United States), Bothell, United States., Zeng W; Pfizer (United States), Bothell, WA, United States., Yumul R; Pfizer (United States), Bothell, United States., Dominguez MM; Danaher (United States), United States., Chen Y; Pfizer (United States), Bothell, United States., Zheng JH; Pfizer (United States), Bothell, United States., Karlsson CAB; Pfizer (United States), Bothell, United States., Trang VH; Pfizer (United States), Bothell, United States., Senter PD; Pfizer, Seattle, WA, United States., Gardai SJ; EpiBiologics, San Mateo, CA, United States.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Oct 28. Date of Electronic Publication: 2024 Oct 28.